Maintenance Therapy Intensification with Palbociclib Improves PFS in HR-Positive, HER2-Positive Metastatic Breast Cancer
In the phase 3 PATINA trial, adding the CDK4/6 inhibitor palbociclib to maintenance HER2-targeted and endocrine therapy significantly prolonged progression-free survival in patients with HR-positive,...
